Lilly

PET scans for Alzheimer's rejected for Medicare pay

PET scans for Alzheimer's rejected for Medicare pay

By

Earlier this year, the Department of Health and Human Services released an action plan for tackling Alzheimer's diagnostics, treatment and funding.

Lilly targets tau in Alzheimer's effort

By

Lilly is upping its bet on Alzheimer's. The Indianapolis-based drug maker announced it has licensed experimental tracers that can hone in on and mark tau tangles that are believed to be a cause of the brain-degenerating disease.